Innovative Product Portfolio Takara Bio offers a comprehensive range of over 10,000 gene and cell engineering research products, including advanced gene synthesis and mRNA production enzymes, creating multiple cross-selling opportunities with laboratories seeking high-quality biotechnological tools.
Expansion and Acquisition Strategy Recent expansions in Europe and strategic acquisitions like Curio Bioscience position Takara Bio as a growing player in spatial biology and single-cell analysis markets, indicating potential for collaborative research projects and joint offerings.
Growing Revenue Streams With annual revenues between $50 million and $100 million, Takara Bio demonstrates strong market presence and financial stability, enabling targeted outreach to pharmaceutical and biotech companies for partnership or contract manufacturing opportunities.
Technological Leadership Launch of innovative systems like the Shasta Single-Cell System and high-quality mRNA enzymes suggests Takara Bio's focus on cutting-edge platforms, opening doors for collaborations with R&D teams investing in next-generation therapies and diagnostics.
Global Market Engagement Active participation in international conferences such as the Human Cell Atlas and collaborations with industry leaders provide avenues to connect with global bioscience organizations seeking innovative research solutions and custom manufacturing services.
$1B$10B
$1B$10B
$500M$1B
$10B
$10B
$1B$10B
$1B$10B
$500M$1BTakara Bio Inc. uses 8 technology products and services including Amazon CloudFront, jQuery UI, Salesforce Marketing Cloud Account Engagement, and more. Explore Takara Bio Inc.'s tech stack below.
| Takara Bio Inc. Email Formats | Percentage |
| First_Last@takarabio.com | 91% |
| First.Last@takarabio.com | 4% |
| Last@takarabio.com | 2% |
| Last_First@takarabio.com | 1% |
| FLast@takarabio.com | 1% |
| First_L@takarabio.com | 1% |
| LastF@takara-bio.co.jp | 100% |
Biotechnology ResearchShiga, Japan1001-5000 Employees
タカラバイオ株式会社は、ライフサイエンス産業の総合ソリューションプロバイダー（プラットフォーマー）です。 1979年に国産初の遺伝子工学研究用試薬（制限酵素）を発売、1988年には日本で初めて遺伝子増幅システムPCRを販売するなど、現在では約１万点におよぶ遺伝子工学・細胞工学研究用製品を扱い、世界のライフサイエンス研究を支援しています。また、国内最大規模の次世代シーケンサーを有して高品質、高付加価値の遺伝子解析受託サービスを展開しているほか、再生・細胞医療・遺伝子治療分野のCDMO(Contract Development and Manufacturing Organization)として製薬企業やバイオベンチャーの開発・製造を支援しています。 タカラバイオは、バイオテクノロジーを通じ健康的な暮らしを笑顔で楽しむSmiles in Lifeを目指しています。
Company Overview
Funding & FinancialsTakara Bio Inc.'s revenue is estimated to be in the range of $50M$100M
Funding & FinancialsTakara Bio Inc.'s revenue is estimated to be in the range of $50M$100M
1-888-653-2347 
support@leadiq.com